Neuroprotective effects of neurokinin receptor one in dopaminergic neurons are mediated through Akt/PKB cell signaling pathway

Neuropharmacology

Volumn 61, Issue 8, 2011, Pages 1389-1398

  Chu, John M T ^a   Chen, L W ^b   Chan, Y S ^c   Yung, Ken K L ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

6 OHDA; Neurokinin; Neurokinin 1 receptor; Neuroprotection; Parkinson's disease

Indexed keywords

APOMORPHINE; G PROTEIN COUPLED RECEPTOR; MITOCHONDRIAL PROTEIN; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR AGONIST; OXIDOPAMINE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SEPTIDE; SUBSTANCE P RECEPTOR;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UPREGULATION;

ANALYSIS OF VARIANCE; ANIMALS; APOMORPHINE; BCL-ASSOCIATED DEATH PROTEIN; CASPASE 3; CELL DEATH; CELL LINE, TUMOR; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; L-LACTATE DEHYDROGENASE; MALE; MOTOR ACTIVITY; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; OXIDOPAMINE; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLIDONECARBOXYLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROKININ-1; ROTAROD PERFORMANCE TEST; SIGNAL TRANSDUCTION; SUBSTANCE P; SYMPATHOLYTICS; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 80053602332     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.08.027     Document Type: Article

References (53)

1. P.M. Abou-Sleiman, M.M.K. Muqit, and N.W. Wood Expanding insights of mitochondrial dysfunction in Parkinson's disease Nat. Rev. Neurosci. 7 2006 207 219 (Pubitemid 43292466)
2. G. Amadoro, M. Pieri, M.T. Ciotti, I. Carunchio, N. Canu, P. Calissano, C. Zona, and C. Severini Substance P provides neuroprotection in cerebellar granule cells through Akt and MAPK/Erk activation: evidence for the involvement of the delayed rectifier potassium current Neuropharmacology 52 2007 1366 1377 (Pubitemid 46601528)
3. J.A. Arias-Montano, D. Martinez-Fong, and J. Aceves Glutamate stimulation of tyrosine hydroxylase is mediated by NMDA receptors in the rat striatum Brain Res. 569 1992 317 322
4. R. Barker Substance P and neurodegenerative disorders. A specific review Neuropeptides 20 1991 73 78
5. R. Barker Tachykinins, neurotrophism and neurodegenerative disease; a critical review on the possible role of tachykinins in the etiology of CNS diseases Rev. Neurosci. 7 3 1996 187 214 (Pubitemid 26397659)
6. J. Bove, D. Prou, C. Perier, and S. Przedborski Toxin-induced models of Parkinson's disease NeuroRx 2 3 2005 484 494 (Pubitemid 41444882)
7. A. Brunet, S.R. Datta, and M.E. Greenberg Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway Curr. Opin. Neurobiol. 11 2001 297 305 (Pubitemid 32524094)
8. N. Calvo, J. Reiriz, E. Perez-Navarro, and J. Alberch Tachykinins protect cholinergic neurons from quinolinic acid excitotoxicity in striatal cultures Brain Res. 740 1996 323 328 (Pubitemid 26411315)
9. S.L. Chan, and M.P. Mattson Caspase and calpain substrates: roles in synaptic plasticity and cell death J. Neurosci. Res. 58 1999 167 190 (Pubitemid 29463702)
10. L.W. Chen, K.K.L. Yung, and Y.S. Chan Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease Curr. Drug Targets 5 2004 197 206 (Pubitemid 38292005)
11. L.W. Chen, Y.Q. Wang, G.L. Bian, L.C. Wei, and K.L. Yung Neurokinin 3 peptide instead of neurokinin 1 synergistically exacerbates kainic acid-inducing degeneration of neurons in the substantia nigra of mice J. Neurochem. 105 2008 203 216
12. B. Cutillas, M. Espejo, J. Gil, I. Ferrer, and S. Ambrosio Caspase inhibition protects nigral neurons against 6-OHDA-induced retrograde degeneration Neuroreport 10 1999 2605 2608 (Pubitemid 29418144)
13. S.R. Datta, H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M.E. Greenberg Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 91 1997 231 241 (Pubitemid 27456390)
14. R. Deumens, A. Blokland, and J. Prickaerts Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway Exp. Neurol. 175 2001 303 317
15. Y.M. Ding, J.D. Jaumotte, A.P. Signore, and M.J. Zigmond Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor J. Neurochem. 89 2004 776 787 (Pubitemid 38534162)
16. T.F. Franke, D.R. Kaplan, and L.C. Cantley PI3K: downstream AKTion blocks apoptosis Cell 88 1997 435 437 (Pubitemid 27154408)
17. T. Futami, Y. Hatanaka, K. Matsushita, and S. Furuya Expression of substance P in the substantia nigra Mol. Brain. Res. 54 2 1998 183 198
18. K. Hanrott, L. Gudmunsen, M. J.O'Neill, and S. Wonnacott 6-hydroxydopamine induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cδ J. Biochem. 281 9 2006 5373 5382 (Pubitemid 43847631)
19. H. Hastrup, and T.W. Schwartz Septide and neurokinin A are high-affinity ligands on the NK1 receptor: evidence from homologous versus heterologous binding analysis FEBS Lett. 399 3 1996 264 266 (Pubitemid 26426863)
20. K.M. Johnson, and Y.J. Jeng Pharmacological evidence for N-methyl-d-aspartate receptors on nigrostriatal dopaminergic nerve terminals Can. J. Physiol. Pharmacol. 69 1991 1416 1421
21. D. Kirik, C. Rosenblad, and A. Bjorklund Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat Exp. Neurol. 152 2 1998 259 277 (Pubitemid 28419264)
22. I.N. Krasnova, E.R. Bychkov, V.I. Lioudyno, O.E. Zubareva, and S.A. Dambinova Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamikne-lesioned rats Neuroscience 95 2000 113 117
23. K. Kuida, T.F. Haydar, C.Y. Kuan, Y. Gu, C. Taya, H. Karasuyama, M.S. Su, P. Rakic, and R.A. Flavell Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9 Cell 94 1998 325 337 (Pubitemid 28376077)
24. F. Lallemend, P.P. Lefebvre, G. Hans, J.M. Rigo, T.r. Van de Water, G. Moonen, and B. Malgrange Substance P protects spiral ganglion neurons from apoptosis via PKC-Ca2+-MAPK/ERK pathways J. Neurochem. 87 2003 508 521 (Pubitemid 37255258)
25. A. Lessard, and V.M. Pickel Subcellular distribution and plasticity of neurokinin 1 receptors in the rat substantia nigra and ventral tegmental area Neuroscience 135 4 2005 1309 1323 (Pubitemid 41416691)
26. M.T. Lin, and M.F. Beal Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases Nature 443 2006 787 795 (Pubitemid 44622683)
27. N. Linderfors, E. Brodin, U. Tossman, J. Segovia, and U. Ungerstedt Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation Exp. Brain. Res. 74 3 1989 527 534 (Pubitemid 19065675)
28. C.A. Maggi Principles of tachykininergic co-transmission in the peripheral and enteric nervous system Regul. Pept. 93 1-3 2000 53 64
29. R. Mattioli, R.K. Schwarting, and J.P. Huston Recovery from unilateral 6-hydroxydopamine lesion of substantia nigra promoted by the neurotachykinin substance P 1-11 Neuroscience 48 1992 595 605
30. A. Mouatt-Prigent, J.O. Karlsson, Y. Agid, and E.C. Hirsch Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience 73 1996 979 987 (Pubitemid 26194324)
31. S. Nakanishi Mammalian tachykinin receptors Annu. Rev. Neurosci. 14 1991 123 136
32. K. Nakaso, S. Ito, and K. Nakashima Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells Neurosci. Lett. 432 2 2008 146 150
33. Y. Nishizuka Protein kinase C and lipid signaling for sustained cellular responses FASEB J. 9 1995 484 496
34. M. Otsuka, and K. Yoshioka Neurotransmitter functions of mammalian tachykinins Physiol. Rev. 73 2 1993 229 308 (Pubitemid 23119035)
35. J. Paez, and W. Sellers PI3K/PTEN/Akt pathway, a critical mediator of oncogenic signaling Cancer Treat. Res. 115 2 2004 145 167
36. A. Parent, F. Cicchetti, and T.G. Beach Striatal neurons displaying substance P (NK1) receptor immunoreactivity in human and nonhuman primates Neuroreport 6 1995 721 724
37. S. Park, Es. Ahn, D.W. Han, J.H. Lee, K.T. Min, H. Kim, and Y.W. Hong Pregabalin and Gabapentin inhibit substance P-induced NF-κB activation in neuroblastoma and glioma cells J. Cell. Biochem. 105 2008 414 423
38. P. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates second ed. 1986 Academic Press
39. L. Pradier, J. Menager, J. Le Guern, M.D. Bock, E. Heuillet, C. FardinGarret, A. Doble, and J.F. Mayaux Septide: an agonist for the NK1 receptor acting at a site distinct from substance P Mol. Pharmacol. 45 2 1993 287 293 (Pubitemid 24063082)
40. A. Quesada, B.Y. Lee, and P.E. Micevych PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease Dev. Neurobiol. 68 2008 632 644 (Pubitemid 351466293)
41. D. Regoli, A. Boudon, and J.L. Fauchere Receptors and antagonists for substance P and related peptides Pharmacol. Rev. 46 4 1994 551 599
42. M.S. Reid, M. Herrera-Marschtz, J. Kehr, and U. Ungerstedt Striatal dopamine and glutamate release: effects of intranigral injections of substance P Acta Physiol. Scand. 140 1990 527 537
43. B. Salthun-Lassalle, S. Traver, E.C. Hirsch, and P.P. Michel Substance P, neurokinin A and B, and synthetic tachykinin peptides protect mesencephalic dopaminergic neurons in culture via an activity-dependent mechanism Mol. Pharmacol. 68 5 2005 1214 1224 (Pubitemid 41539979)
44. A. Schober Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP Cell Tissue Res. 318 2004 215 224 (Pubitemid 39366054)
45. C. Severini, G. Improta, G. Falconieri-Erspamer, S. Salvadori, and V. Erspamer The tachykinin peptide family Pharmacol. Rev. 54 2002 285 332
46. C. Severini, M.T. Ciotti, D. Mercanti, C. Barbato, and P. Calissano A tachykinin-like factor increases glutamate toxicity in rat cerebellar granle cells Neuropharmacology 44 2003 117 124 (Pubitemid 36135849)
47. Q.B. She, D.B. Solit, Q. Ye, K.E. O'Reilly, J. Lobo, and N. Rosen The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells Cancer Cell 8 2005 287 297 (Pubitemid 41443414)
48. K. Shimoke, and H. Chiba Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease J. Neurosci. Res. 63 2001 402 409 (Pubitemid 32183789)
49. E.A. Slee, M.T. Harte, R.M. Kluck, B.B. Wolf, C.A. Casiano, D.D. Newmeyer, H.G. Wang, J.C. Reed, D.W. Nicholson, E.S. Alnemri, D.R. Green, and S.J. Martin Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner J. Cell. Biol. 144 1999 281 292 (Pubitemid 29066031)
50. O. Tenovuo, U.K. Rinne, and M.K. Viljanen Substance P immunoreactivity in the post-mortem parkinsonian brain Brain Res. 303 1 1984 113 116 (Pubitemid 14122511)
51. O. Tenovuo, O. Kolhinen, A. Laihinen, and U.K. Rinne Brain substance P receptors in Parkinson's disease Adv. Neurol. 53 1990 145 148
52. U. Wormser, R. Laufer, Y. Hart, M. Chorev, C. Gilon, and Z. Selinger Highly selective agonists for substance P receptor subtypes EMBO J. 5 11 1986 2805 2808
53. M.J. Zigmond, S.L. Castro, K.A. Keefe, E.D. Abercombie, and A.F. Sved Role of excitatory amino acids in the regulation of dopamine synthesis and release in the neostriatum Amino Acids 14 1998 57 62 (Pubitemid 28051152)